• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Time to treatment of uveal melanoma in the United Kingdom.

作者信息

Damato B

机构信息

Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital, UK.

出版信息

Eye (Lond). 2001 Apr;15(Pt 2):155-8. doi: 10.1038/eye.2001.51.

DOI:10.1038/eye.2001.51
PMID:11339581
Abstract

PURPOSE

To measure delay before treatment of uveal melanoma.

METHODS

A retrospective study was carried out of patients referred for diagnosis and treatment of uveal melanoma at the Liverpool Ocular Oncology Centre (LOOC), a tertiary adult ocular oncology service. Participants were patients with uveal melanoma presenting to an optometrist or general practitioner in the United Kingdom between 1997 and 2000. Main outcome measures were delay at each stage of the referral process according to route of referral and tumour size.

RESULTS

Delays greater than 2 weeks occurred (1) between presentation to the optometrist or general practitioner and the ophthalmologist's examination in 50% of patients; (2) between the ophthalmologist's examination and receipt of the referral at the ocular oncology centre in 34%; (3) between receipt of referral at the oncology centre and first assessment at that centre in 16%; and (4) between first assessment at the oncology centre and treatment in 8%. The waiting time for the ophthalmologist's examination was greater if the optometrist referred the patient via the general practitioner instead of directly. The median overall delays between presentation and treatment were 129 days for small tumours, 50 days for medium-sized tumours and 34 days for large tumours.

CONCLUSIONS

Many patients with uveal melanoma experience long delays before treatment. Patients wait longer to see an ophthalmologist if their tumour is small or if they are referred by the optometrist to the general practitioner instead of directly to the ophthalmologist. Several patients also experience long delays after seeing the ophthalmologist, some having a large tumour by the time of teatment.

摘要

相似文献

1
Time to treatment of uveal melanoma in the United Kingdom.
Eye (Lond). 2001 Apr;15(Pt 2):155-8. doi: 10.1038/eye.2001.51.
2
Delays in the diagnosis of uveal melanoma and effect on treatment.葡萄膜黑色素瘤的诊断延误及其对治疗的影响。
Eye (Lond). 1998;12 ( Pt 5):781-2. doi: 10.1038/eye.1998.202.
3
Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients.英国葡萄膜黑色素瘤的检测和治疗时机:2384 例患者的评估。
Ophthalmology. 2012 Aug;119(8):1582-9. doi: 10.1016/j.ophtha.2012.01.048. Epub 2012 Apr 11.
4
Preventable delays in the treatment of intraocular melanoma in the UK.
Eye (Lond). 1996;10 ( Pt 1):127-9. doi: 10.1038/eye.1996.22.
5
Mode of presentation and time to treatment of uveal melanoma in Finland.芬兰葡萄膜黑色素瘤的临床表现及治疗时间
Br J Ophthalmol. 2002 Mar;86(3):333-8. doi: 10.1136/bjo.86.3.333.
6
Nondiagnosed uveal melanomas.未确诊的葡萄膜黑色素瘤。
Ophthalmology. 2004 Mar;111(3):554-7. doi: 10.1016/j.ophtha.2003.07.002.
7
Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.1979年至2003年期间瑞典人群中葡萄膜黑色素瘤的钌近距离放射治疗:生存及功能结果
Ophthalmology. 2005 May;112(5):834-40. doi: 10.1016/j.ophtha.2004.11.038.
8
Uveal melanoma in Israel in the last two decades: characterization, treatment and prognosis.以色列过去二十年的葡萄膜黑色素瘤:特征、治疗与预后
Isr Med Assoc J. 2009 May;11(5):280-5.
9
Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.碘近距离放射治疗作为大型葡萄膜黑色素瘤眼球摘除术的替代方法。
Ophthalmology. 2003 Nov;110(11):2223-34. doi: 10.1016/S0161-6420(03)00661-4.
10
Metastatic melanoma in the eye and orbit.眼部和眼眶转移性黑色素瘤。
Ophthalmology. 2003 Nov;110(11):2245-56. doi: 10.1016/j.ophtha.2003.05.004.

引用本文的文献

1
Performance of the MOLES and TFSOM-DIM scores in classifying choroidal nevi and melanoma.MOLES 和 TFSOM-DIM 评分在脉络膜痣和黑色素瘤分类中的表现。
Sci Rep. 2024 Nov 18;14(1):28534. doi: 10.1038/s41598-024-78692-w.
2
Small High-Risk Uveal Melanomas Have a Lower Mortality Rate.小型高危葡萄膜黑色素瘤的死亡率较低。
Cancers (Basel). 2021 May 8;13(9):2267. doi: 10.3390/cancers13092267.
3
Transcriptome Profiling Reveals New Insights into the Immune Microenvironment and Upregulation of Novel Biomarkers in Metastatic Uveal Melanoma.
转录组分析揭示了转移性葡萄膜黑色素瘤免疫微环境的新见解及新型生物标志物的上调。
Cancers (Basel). 2020 Sep 30;12(10):2832. doi: 10.3390/cancers12102832.
4
Uveal Melanoma: Current Trends in Diagnosis and Management.葡萄膜黑色素瘤:诊断与治疗的当前趋势
Turk J Ophthalmol. 2016 Jun;46(3):123-137. doi: 10.4274/tjo.37431. Epub 2016 Jun 6.
5
Primary care and ophthalmology in the United Kingdom.英国的初级医疗保健与眼科
Br J Ophthalmol. 2003 Apr;87(4):493-9. doi: 10.1136/bjo.87.4.493.
6
Mode of presentation and time to treatment of uveal melanoma in Finland.芬兰葡萄膜黑色素瘤的临床表现及治疗时间
Br J Ophthalmol. 2002 Mar;86(3):333-8. doi: 10.1136/bjo.86.3.333.